Hepion files amended balance sheet to correct warrant accounting; $6.14M warrant liability recorded

Hepion Pharmaceuticals, Inc.

Amended 8-K/A filed to correct accounting for Series A and B warrants issued in Jan 2025 offering.
Unaudited balance sheet as of Jan 31, 2025 shows cash $5.22M and total assets $6.36M.
Derivative financial instruments-warrants liability of $6.14M recorded, exceeding total stockholders' equity of ($23,916).
Prepaid expenses $1.14M; accounts payable $220K; accrued expenses $23.7K.
No other changes to original 8-K filed March 4, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.